Important safety information
INDICATION: Wynzora® (calcipotriene and betamethasone dipropionate) Cream,
0.005%/0.064% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and
older. ADVERSE EVENTS: In the pivotal trial, the most common adverse reactions (≥1%)
were: upper respiratory infection (7%), headache (2%), and application site infection (1%).
WARNINGS AND PRECAUTIONS: For topical use only. Patients should not use more than 100g of
Wynzora® Cream per week. Do not use near or in the mouth, eyes or intravaginally. Avoid using Wynzora®
Cream on the face, groin or armpits, or if they have atrophy at the treatment site. Discontinue use once
plaque psoriasis is under control or at 8 weeks. Do not use Wynzora® Cream with occlusive dressings.
Hypercalcemia and hypercalciuria have been observed with topical use of calcipotriene. Wynzora® Cream can
cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency
during and after withdrawal of treatment. Wynzora® Cream may cause vision problems, including increasing
the risk of cataracts and glaucoma. It is not known if Wynzora® Cream may harm your unborn baby.
Breastfeeding women should not apply Wynzora® Cream directly to the nipple or areola; it is not known
whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.
Full Prescribing Information for
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
Reference: 1. Data on File. MC2 Therapeutics.